Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer drug trial halted early: what happened?

NCT ID NCT04189614

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called cofetuzumab pelidotin for people with a specific type of advanced lung cancer (non-small cell lung cancer) that had returned after other treatments. The drug was designed to target a protein called PTK7 found on cancer cells. The study was stopped early, and results are limited. It involved 65 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

65 people

The number who actually took part.

Started

Feb 2020

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed non-small cell lung cancer (NSCLC) with PTK7-expressing tumor using an immunohistochemistry (IHC) assay previously validated at a designated laboratory * Recurrent NSCLC that has progressed after treatment with at least the following approved therapies with demonstrated clinical benefit: a platinum-based chemotherapy doublet and an immune checkpoint inhibitor for tumors without targetable genetic alterations; a platinum-based chemotherapy doublet and targeted agent(s) for tumors with targeted genetic alterations * Received ≤ 2 prior lines of systemic therapy, including no more than 1 line of systemic cytotoxic chemotherapy (≤ 3 prior lines for tumors treated with targeted agent(s) for genetic alterations, including no more than 1 line of systemic chemotherapy) * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Adequate bone marrow, renal, and hepatic function per the protocol Exclusion Criteria: * Known uncontrolled metastases to the central nervous system (CNS). Participants with CNS metastases may be eligible provided that definitive therapy has been given, and participants are asymptomatic and off systemic steroids and anticonvulsants used for management of brain metastases for at least 2 weeks prior to the first dose of study drug * Unresolved clinically significant adverse events Grade ≥ 2 from prior anticancer therapy (with the exception of alopecia or anemia) * Has clinically significant medical condition(s) as described in the protocol * Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days prior to the first dose of study drug (no washout period required for participants on EGFR tyrosine kinase inhibitors). Palliative radiation therapy for bone, skin or subcutaneous metastases with 10 fractions or less is not subject to a washout period * Received anti-cancer herbal therapies within 7 days prior to the first dose of study drug

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Non-small cell lung cancer (NSCLC)

Contacts and locations

Locations

  • Asan Medical Center /ID# 222280

    Seoul, Seoul Teugbyeolsi, 05505, South Korea

  • CHA Bundang Medical Center /ID# 232514

    Seongnam, Gyeonggido, 13496, South Korea

  • Duplicate_Stanford University School of Med /ID# 213450

    Stanford, California, 94305-2200, United States

  • Highlands Oncology Group, PA /ID# 215383

    Springdale, Arkansas, 72762, United States

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 215110

    Madrid, 28040, Spain

  • Hospital Universitario HM Sanchinarro /ID# 215102

    Madrid, 28050, Spain

  • Hospital Universitario Vall de Hebron /ID# 215729

    Barcelona, 08035, Spain

  • Linkou Chang Gung Memorial Hospital /ID# 222603

    Taoyuan City, 333, Taiwan

  • Moffitt Cancer Center /ID# 215101

    Tampa, Florida, 33612-9416, United States

  • National Cancer Center Hospital /ID# 218536

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 218537

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital /ID# 222602

    Tainan, 704, Taiwan

  • Oncology Consultants /ID# 215932

    Houston, Texas, 77030-3306, United States

  • Rabin Medical Center. /ID# 217537

    Petah Tikva, Central District, 4941492, Israel

  • Rambam Health Care Campus /ID# 217536

    Haifa, 3109601, Israel

  • Samsung Medical Center /ID# 222906

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Sylvester Comprehensive Cancer Center /ID# 216433

    Miami, Florida, 33136-1002, United States

  • Tennessee Oncology, PLLC /ID# 215326

    Nashville, Tennessee, 37203, United States

  • The Chaim Sheba Medical Center /ID# 217538

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The Ohio State University /ID# 211088

    Columbus, Ohio, 43210, United States

  • Univ of Colorado Cancer Center /ID# 215295

    Aurora, Colorado, 80045, United States

  • University of Alabama at Birmingham - Main /ID# 213605

    Birmingham, Alabama, 35233, United States

  • University of Texas MD Anderson Cancer Center /ID# 215876

    Houston, Texas, 77030, United States

  • Virginia Cancer Specialists - Fairfax /ID# 216427

    Fairfax, Virginia, 22031, United States

  • Washington University-School of Medicine /ID# 213453

    St Louis, Missouri, 63110, United States

  • Yonsei University Health System Severance Hospital /ID# 222281

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.